TNNT2 and prostate carcinoma: For the prostate cancer endpoint, NT-proBNP was statistically significant in the minimally adjusted model (HR: 1.20; 95% CI: 1.00-1.44; P = 0.049) but not in the fully adjusted model, while hs-cTnT was not significant in either.